Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

ClinicalTrials.gov ID: NCT03248479

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03248479. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives of this study are: * To confirm the safety and tolerability of magrolimab monotherapy in a relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) population, and of magrolimab in combination with azacitidine in previously untreated participants with AML or MDS and participants with R/R AML and MDS * To evaluate the efficacy of magrolimab monotherapy in R/R AML/MDS, and of magrolimab in combination with azacitidine in previously untreated participants with AML/MDS, or R/R AML/MDS as measured by complete remission (CR) rate for participants with AML and higher-risk MDS, and duration of complete response for participants with AML and higher-risk MDS, and duration of CR for participants with AML and higher-risk MDS * To evaluate the safety, tolerability, and efficacy of magrolimab monotherapy or combination with azacitidine in low-risk MDS participants as measured by red blood cell (RBC) transfusion independence rate

Study identification

NCT ID: NCT03248479
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Gilead Sciences; Industry
Enrollment: 258 participants

Conditions and interventions

Conditions

Hematological Malignancies

Interventions

Magrolimab Drug
Azacitidine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 8, 2017 (Actual)
Primary completion: Sep 5, 2023 (Actual)
Completion: Sep 5, 2023 (Actual)
Last update posted: Jan 17, 2025

2017 – 2023

United States locations

U.S. sites: 26
U.S. states: 13
U.S. cities: 23

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010	—
University of California San Diego (UCSD)	La Jolla	California	92093	—
UCLA Clinical and Translational Research Center (CTRC)	Los Angeles	California	90095	—
Chao Family Comprehensive Cancer Center - UC Irvine Medical Center	Orange	California	92868	—
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	—
Stanford University Medical Center	Stanford	California	94305	—
University of Colorado Cancer Center	Aurora	Colorado	80045	—
University Of Miami - Miller School Of Medicine, Sylvester Comprehensive Cancer Center	Miami	Florida	33136	—
H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida	33612	—
The University of Chicago	Chicago	Illinois	60637	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute/ Boston Children's Hospital	Boston	Massachusetts	02215	—
Mid America Division, Inc.	Kansas City	Missouri	64132	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Weill Cornell Medical College - New York-Presbyterian Hospital	New York	New York	10021	—
Icahn School of Medicine at Mount Sinai	New York	New York	10029	—
Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center	New York	New York	10032	—
Montefiore Medical Center	The Bronx	New York	10467	—
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
Duke University Medical Center	Durham	North Carolina	27705	—
Ohio State University Medical Center	Columbus	Ohio	43210	—
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	—
Tennesssee Oncology - Centennial Clinic Location	Nashville	Tennessee	37203	—
Texas Oncology - Baylor Charles A. Simmons Cancer Center	Dallas	Texas	75246	—
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
Medical College of WI Froedtert Hospital	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03248479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 17, 2025 · Synced Nov 14, 2026